Search / Trial NCT06617026

Short-Term Outcome of Medical Vs. Surgical Management Of Chronic Anal Fissure

Launched by SUEZ CANAL UNIVERSITY · Sep 25, 2024

Trial Information

Current as of October 07, 2024

Recruiting

Keywords

Chronic Anal Fissure

Description

Several topical agents have been proposed for Chronic anal fissure (CAF) treatment with the common goal of increasing anodermal blood flow to promote healing but approaching the use of medical treatment in CAFs is not standardized yet. Thus, the present study aimed to compare the efficacy and safety of Sucralfate (Emoflon®), the combination of azadirachtin and hyperforin (HyperOil®) and the traditional surgical treatment (lateral sphincterotomy) in patients with CAFs. Study Objective: Primary Objectives: 1. To evaluate the efficacy and safety of Sucralfate (Emoflon®), the combination of ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * above 18 years old.
  • * CAFs for the first time
  • * ASA I, II
  • Exclusion Criteria:
  • * Sepsis
  • * Previous pelvic radiation.
  • * recurrent chronic anal fissure
  • * Pregnancy or lactation.
  • * Immunosuppressive state
  • * Malignancy
  • * Refusal to participate

About Suez Canal University

Suez Canal University is a distinguished academic institution dedicated to advancing medical research and education in the region. As a clinical trial sponsor, the university focuses on conducting innovative studies that aim to enhance patient care and outcomes. Leveraging its strong network of healthcare professionals and state-of-the-art facilities, Suez Canal University fosters collaboration between researchers and clinicians to explore new therapeutic approaches and validate clinical practices. Committed to ethical standards and scientific rigor, the university plays a pivotal role in contributing to the global body of medical knowledge and improving healthcare delivery.

Locations

Ismailia, , Egypt

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0